The FDA has approved Merck’s Capvaxive, a vaccine for adults that targets pneumococcus bacteria, which can lead to pneumonia and other severe infections. An advisory panel from the CDC will decide on June 27 who should receive the vaccine.

Analysts expect Capvaxive to become a significant revenue source for Merck, especially as it aims to counteract the impending revenue decline from its cancer drug Keytruda.